Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network

Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Swiss medical weekly Jg. 155; H. 7; S. 4219
Hauptverfasser:	Rieger, Max J., Flammer, Andreas J., Gerull, Sabine, Pabst, Thomas, Auner, Holger W., Samii, Kaveh, Hitz, Felicitas, Mey, Ulrich, Ballova, Veronika, Battegay, Raphael, Melli, Giorgia, Benz, Dominik, Yakupoglu, Yakup, Gräni, Christoph, Schläger, Regina, Hugelshofer, Sarah, Studer, Annina, Oechslin, Luca, Bakula, Adam, Suter, Thomas M., Leo-Stickelberger, Julia, Averiamo, Manuela, Fehr, Thomas, Jung, Hans H., Laptseva, Natallia, Manka, Robert, Rüfer, Axel, Schmidt, Adrian, Seeger, Harald, Müllhaupt, Beat, Stämpfli, Simon F., De Ramon Ortiz, Carmen, Théaudin, Marie, Gerber, Bernhard, Schwotzer, Rahel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 17.07.2025
Schlagworte:	Antibodies, Monoclonal - therapeutic use Bortezomib - therapeutic use Cyclophosphamide - therapeutic use Dexamethasone - therapeutic use Humans Immunoglobulin Light-chain Amyloidosis - drug therapy Immunoglobulin Light-chain Amyloidosis - therapy Practice Guidelines as Topic Switzerland Switzerland
ISSN:	1424-3997, 1424-3997
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous “therapeutic recommendations” while the previous “diagnostic recommendations” remain valid.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1424-3997 1424-3997
DOI:	10.57187/s.4219